Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of tumors and subdivided into specified and not otherwise specified (NOS) types. Clinically, the International Prognostic Index (IPI), Prognostic Index for T-cell lymphoma, and Bologna score have been the prognostic model to discriminate the prognosis of patients with PTCL-NOS. However, no simple prognostic marker has been satisfactory in predicting treatment outcomes in patients with PTCL-NOS.
From Sep 2005 to Aug 2016, we identified 94 patients diagnosed with PTCL-NOS initially treated with CHOP or CHOP-like regimens. Event-free survival (EFS) was calculated from the date of diagnosis to the date of disease progression, treatment failure, relapse, or death from any cause. Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause. The cut-off of serum β2-microgloulin (B2MG) was defined as > 3.2 mg/L.
Among 94 patients, 41 (43.6%) patients showed B2MG > 3.2 mg/L, 37 (39.4%) patients showed B symptoms. According to IPI scores, 19 (20.2%) patients belonged to the low risk group (L), 25 (26.6%) to the low-intermediate (LI), 29 (30.9%) to the high-intermediate (HI), and 21 (22.3%) to the high (H). Complete response (CR), EFS, and OS were associated with B2MG, B symptoms, performance status, lactate dehydrogenase, extranodal involvement, Ann Arbor stage, and IPI risk group in univariate analysis. After multivariate analysis, B2MG was associated with CR (> 3.2 mg/L vs. ≤3.2 mg/L, odd ratio [OR]: 4.053, 95% confidence interval [CI]: 1.314–12.503, P = 0.015), EFS (hazard ratio [HR]: 1.721, 95% CI: 1.026–2.887, P = 0.040), but OS (HR: 1.449, 95% CI: 0.803–2.615, P = 0.218). IPI risk group was associated with CR (L/LI vs. HI/H, P = 0.022), EFS (P < 0.001), and OS (P < 0.001). In 50 patients of HI/H risk group, B2MG showed association with CR (OR: 5.464, 95% CI: 1.256–23.774, P = 0.024), EFS (HR: 2.160, 95% CI: 1.095–4.260, P = 0.026), and OS (HR: 2.158, 95% CI: 0.979–4.759, P = 0.057).
B2MG could be a simple prognostic factor for the patients with PTCL-NOS. B2MG > 3.2 mg/L was associated with worse prognosis of patients with PTCL-NOS, especially in HI/H risk group. The larger scaled study is warranted to confirm our result.
Clinical trial identification
Legal entity responsible for the study
Byeong Seok Sohn.
Has not received any funding.
All authors have declared no conflicts of interest.